Microbion Receives Award at Advanced Wound Care Summit USA's Innovation Showcase

News provided by

Apr 25, 2024, 08:05 ET

Microbion wins Innovation Showcase Award at Advanced Wound Care Summit USA 2024

BOZEMAN, Mont. and VANCOUVER, BC, April 25, 2024 /PRNewswire/ - Microbion Corporation today announced that the company won the Advanced Wound Care Summit's Innovation Showcase award. The Innovation Showcase was designed to give presenters, who were picked by a selection committee, an opportunity to demonstrate their vision of the future of wound care, and how their product, technology, or service fits into it. The presentation was focused on topical pravibismane's clinical safety and efficacy for the treatment of moderate to severe diabetic foot ulcer infection (DFI) and future development plans.

"We would like to thank the selection committee for recognizing topical pravibismane's innovation as a multimodal therapeutic with the potential to significantly impact patients' lives and give health care providers a new therapeutic option that addresses several unmet needs in the treatment of infected diabetic foot ulcers," said Karim Lalji, Microbion's CEO. "We praise the efforts of our fellow presenters whose technologies also have the potential to impact the lives of patients."

In a Phase 1b study in patients with moderate to severe DFI, pravibismane was well-tolerated and pravibismane treated subjects showed an approximately 3-fold reduction in ulcer size compared to the placebo group (85% versus 30%). Furthermore, the incidence of diabetic ulcer-related lower limb amputations was approximately 6-fold lower in the pooled pravibismane group compared to the placebo group (2.6% versus 15.4%). Topically applied pravibismane has the potential to address several unmet medical needs for the successful treatment of DFI by simultaneously treating bacterial biofilm-related infections and accelerating ulcer size reduction, potentially leading to complete re-epithelialization and wound closure along with reduction of reinfection and amputation risks.

The company has recently completed a Phase 2 study assessing the safety, tolerability, and wound closure efficacy of a higher concentration and longer, 12-week dosing duration of topical pravibismane in patients with moderately infected chronic diabetic foot ulcers.

About Microbion

Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion's lead drug candidate, pravibismane, is the first product in this new class and has multiple novel modes of action, including potent broad spectrum anti-infective, antibiofilm, and immuno-modulatory activity, offering unique potential to address the unmet needs of chronic and severe health conditions. Topical pravibismane is completing Phase 2 development for the treatment of chronic wounds. Local pravibismane is in Phase 2 clinical development for orthopedic infections and inhaled pravibismane is advancing into Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $20 million in non-dilutive grants. The FDA has granted pravibismane Orphan Drug, Fast Track, and Qualified Infectious Disease Product (QIDP) designations.

For more information visit: www.microbioncorp.com.

Safe Harbor Statement

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Microbion Corporation